Nanoparticles in Blood: Understanding and Controlling Protein Corona for Optimized Nanomedicine (NANOBLORONA)

University Hospital Center (CHU) Dijon Bourgogne

Status: Not yet enrolling

Conditions: Coagulation Tests

Treatments: Other: blood tests

Study type: Observational

Funder types: Other

Identifiers

NCT05690542

DEMAISTRE CNRS 2022

Details and patient eligibility

About

The main objective is to study the effect of engineered nanoparticles SPIONs (superparamagnetic iron oxide) on hemostasis. Nanoparticles will be incubated in blood and platelet aggregation will be measured. In parallel, nanoparticles will also be incubated in blood and then plasma proteins adsorbed on them will be separated and analyzed. The proteins found on the nanoparticles will be linked to the platelet aggregation observed to help developing innovative protein functionalized nanoprobes for optimized nanomedicine.

Enrollment: 60 estimated patients

Sex: All

Ages: 18 to 79 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• all people

Exclusion criteria

• patient under 18 years old, legal protection measure, pregnancy

Trial design

60 participants in 2 patient groups

patients from intensive care units

Description:

patients with hemostasis disorders (coagulation and/or platelets), antiplatelet and/or anticoagulant treatment

Treatment:

Other: blood tests

controls

Description:

healthy people

Treatment:

Other: blood tests